Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : Novo Nordisk Plan NASH Collaboration

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2019 | 06:26am EDT

By Colin Kellaher

Gilead Sciences Inc. (GILD) and Novo Nordisk A/S (NOVO-B.KO, NVO) on Friday said they will collaborate on a clinical trial combining compounds from their pipelines in nonalcoholic steatohepatitis, a chronic liver condition commonly known as NASH.

The companies said the trial will be a proof-of-concept study combining Novo's semaglutide and Gilead's cilofexor and firsocostat for the treatment of patients with NASH.

Gilead, a Foster City, Calif., biopharmaceutical company, and Danish pharmaceutical company Novo said they also may collaborate on preclinical research to advance understanding of the disease, which often affects people with diabetes and metabolic syndrome.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES 2.73% 68.07 Delayed Quote.8.82%
NOVO NORDISK AS 0.84% 320.2 Delayed Quote.6.53%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
08:32aGILEAD SCIENCES : Kite Announces Plans to Bolster Industry-Leading Cell Therapy ..
BU
07/15S&P ends near flat as Citigroup results sink banks; Nasdaq hits new high
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15MARKET SNAPSHOT: Stocks Eke Out Another Round Of Records As Investors Brace F..
DJ
07/15Europe closes higher as upbeat China data boosts German shares
RE
07/15WALL STREET STOCK EXCHANGE : U.S. Stocks Tread Water
DJ
07/15GLOBAL MARKETS LIVE : Facebook, Gilead, AB Inbev, Boeing…
07/15Stocks to Watch: Circor International, Callon Petroleum, American Airlines, B..
DJ
07/15The Galapagos drugs pipeline that has drawn in Gilead
RE
More news
Financials (USD)
Sales 2019 22 005 M
EBIT 2019 11 453 M
Net income 2019 7 013 M
Debt 2019 2 514 M
Yield 2019 3,70%
P/E ratio 2019 12,4x
P/E ratio 2020 12,3x
EV / Sales2019 4,05x
EV / Sales2020 3,71x
Capitalization 86 555 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,7  $
Last Close Price 68,1  $
Spread / Highest target 39,6%
Spread / Average Target 18,5%
Spread / Lowest Target -13,3%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES8.82%84 164
VERTEX PHARMACEUTICALS6.43%45 080
REGENERON PHARMACEUTICALS-20.16%31 857
SAREPTA THERAPEUTICS INC43.78%11 437
GENMAB11.33%11 148
ARRAY BIOPHARMA INC225.75%10 445